World Molecular Diagnostics for Cancer Markets Report 2023: The New Automation, Decentralization and Point Of Care

Rhea-AI Summary

The Molecular Diagnostics for Cancer report, released on February 9, 2023, provides comprehensive data to analysts and planners, including the latest Medicare Fee Payment Schedules for test pricing. It emphasizes growth in pharmacogenomics, personalized medicine, and liquid biopsy, projecting a dynamic global market despite potential disruptions from the COVID-19 pandemic. The report details market insights across 18 countries and includes profiles of over 120 companies. Key trends such as the emergence of new economies and the role of genetic material in health are highlighted, showing a promising outlook for the diagnostics industry.

Positive

• The report highlights opportunities in personalized medicine and pharmacogenomics, indicating market potential.
• In-depth analysis of testing regimes allows for better planning and investment decisions.
• The inclusion of a new segment, Cancer Companion Diagnostics, could reshape the market.

Negative

• The COVID-19 pandemic may disrupt growth potential by reallocating resources.
• Falling prices in the market could limit revenue growth.

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization" report has been added to  ResearchAndMarkets.com's offering.

Molecular Diagnostics for Cancer report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report.

The report includes a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 120 companies are profiled.

A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• Personalized medicine
• Pharmacogenomics
• Liquid biopsy
• Emergence of new economies with large markets
• Greater understanding of the role of genetic material in Disease and Health

Key Topics Covered:

1 Market Guides
1.1 Cancer MDx - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview
3.1 Market Segments
3.1.1 Traditional Market Segmentation
3.1.2 Laboratory Focus and Segmentation
3.2 Industry Structure
3.2.1 Hospital Testing Share
3.2.2 Economies of Scale
3.2.3 Physician Office Labs
3.2.4 Physicians and POCT

4 Market Trends
4.1 Factors Driving Growth
4.1.1 New Diagnostics Create New Markets
4.1.2 New Roles for Diagnostics
4.1.3 The Aging Effect
4.1.4 Expanding the Pharmaceutical Toolbox
4.1.5 Regulatory Retreat
4.2 Factors Limiting Growth
4.2.1 Falling Prices
4.2.2 Lower Costs
4.2.3 Wellness has a Downside
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
4.3.11 Multiplexing and Foundation One
4.3.12 Pharmacogenomics Technology
4.3.13 Gene Editing and Gene Therapy

5 Molecular Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Sema4 Exiting Reproductive Health Screening
5.3 Thermo Fisher Introduces Cancer Profiling Assay
5.4 Genomic Test IDs Cysts Likely to Progress to Cancer
5.5 Naveris to Commercialize Virus-Related Cancer Tests
5.6 Larger Liquid Biopsy Panels Loom
5.7 Halo Diagnostics to Offer Genomic Profiling Tests
5.8 BillionToOne Raises $125M
5.9 Local Cancer Genomic Profiling Options Grow
5.10 German MDx Firm Mainz Biomed Raises $10M in IPO
5.11 Guardant Health Q3 Revenues Up 27 Percent
5.12 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
5.13 Nucleix to Invest in Early-Stage Lung Cancer Dx
5.14 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
5.15 Grail Gets Approval for Galleri Multicancer Test
5.16 Finnish Firms to Form Point-of-Care Testing Firm
5.17 Datar Cancer Genetics Expands to Dx and Screening
5.18 HTG Molecular Diagnostics: HTG Transcriptome Panel
5.19 PacBio's Omniome Acquisition Shortens Path to Clinical
5.20 Invitae to Acquire Genosity for $200M
5.21 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
5.22 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
5.23 Natera Revenues Grow 35 Percent
5.24 AnchorDx Closes $40M Financing Round
5.25 Exact Sciences Strategy for End-to-End Cancer Testing
5.26 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6 Profiles of Key MDx Companies

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Aethlon Medical
• Agilent/Dako
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• BillionToOne
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bolidics
• Boreal Genomics
• Bristol-Myers Squibb
• Burning Rock
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellCarta
• CellMax Life
• Cepheid (Danaher)
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences
• Freenome
• FUJIFILM Wako Diagnostics
• Fulgent Genetics
• Fyr Diagnostics
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HeiScreen
• Helomics
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Integrated Diagnostics
• Invitae Corporation
• Invivogen
• Invivoscribe
• Janssen Diagnostics
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics/Myriad RBM
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene Bioinformatics Technology Co., Ltd.
• Oncocyte
• OncoDNA
• Ortho Clinical Diagnostics
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Perkin Elmer
• Personal Genome Diagnostics
• Personalis
• Precipio
• Precision Medicine Group
• PrecisionMed
• Predicine
• Promega
• Qiagen
• Rarecells SAS
• RareCyte
• Roche Molecular Diagnostics
• Screencell
• Sema4 Holdings
• Sense Biodetection
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singulomics
• SkylineDx
• Standard BioTools
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.
• Todos Medical
• Variantyx
• Veracyte
• Volition
• Vortex Biosciences
• Vyant Bio
• Zhejiang Orient Gene Biotech

For more information about this report visit https://www.researchandmarkets.com/r/vdbwad

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/world-molecular-diagnostics-for-cancer-markets-report-2023-the-new-automation-decentralization-and-point-of-care-301742974.html

SOURCE Research and Markets

FAQ

What does the Molecular Diagnostics for Cancer report cover?

The report covers market forecasts, cancer types, product insights, and pricing schedules.

When was the Molecular Diagnostics for Cancer report released?

The report was released on February 9, 2023.

What are the key trends in the Molecular Diagnostics for Cancer market?

Key trends include personalized medicine, pharmacogenomics, and liquid biopsy.

How many companies are profiled in the report?

Over 120 companies are profiled in the report.

What impact does COVID-19 have on the Molecular Diagnostics for Cancer market?

COVID-19 may disrupt growth due to resource reallocation.

What market regions are analyzed in the report?

The report includes detailed breakouts for 18 countries and 4 regions.